Abstract
Increased attention has surrounded spinal cord stimulation’s (SCS) long-term effectiveness and methods to improve patient selection. SCS trialing with documentation of pain relief ≥ 50% as a prerequisite for implantation is commonly utilized, which was reinforced by government agencies (e.g., FDA).1 However, the utility, reporting protocols, and evidence surrounding the long-term prognostic value of trialing are questioned.2,3 The purpose of this study is to analyze the influence of SCS trial reported pain results to accurately predict short, intermediate, and long-term pain outcomes, as well as identify possible patient-specific confounding variables.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Neuromodulation: Technology at the Neural Interface
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
